About Genetic disorders and Gene therapy
- Home |
- About Genetic disorders and Gene therapy
About the Conference
International Conference and Expo on Genetic Disorders and Gene Therapy have been scheduled during May 15-16, 2023, at Istanbul, Turkey. This conference mainly discusses about the genetic variations, gene therapy, human genome and also recent advances in genetics, genetic disorders and gene therapy. The recent trends in genetics involves mRNA treatment for cancer, gene network changes associated with cancer onset & progression identify new treatment targets, genome structural variation etc.
Why to attend this Conference?
Be the first to showcase your research, innovations and the brand to attain competitive advantages. Meet your target audience and explore your knowledge about the research work.
Genetics & Molecular Biology Universities
Genetics & Molecular Biology Associations and Societies
Over 7,000 rare diseases have been documented to affect over 400 million individuals worldwide. Between 3.5% and 5.9% of people worldwide suffer from rare diseases. 72% of rare diseases are inherited, while others are brought on by bacterial or viral infections, asthma, environmental factors, or are proliferative and degenerative in nature. About 70% of genetically rare disorders start when a child is young. Relatively common symptoms can mask unique underlying illnesses, leading to delayed identification and treatment. The patient's quality of life is significantly impacted by the lack of mobility loss brought on by the condition's chronic, deteriorating, degenerative, and frequently fatal symptoms. Thus, it is projected that the increasing number of people with rare diseases would fuel the gene therapy application during the forecast period.
The worldwide cell and gene therapy manufacturing services market is expected to reach USD 13.8 billion by 2026, up from USD 7.7 billion in 2021, at a CAGR of 12.4% over the forecast period. The high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increased partnerships and agreements between pharmaceutical companies and CDMOs are driving growth in the cell & gene therapy manufacturing services market. The high operating expenses associated with cell and gene therapy manufacturing, on the other hand, are projected to limit the growth of the cell and gene therapy manufacturing services market to some extent.
The market for rare illness genetic testing is predicted to be worth US$ 900 million in 2020 and US$ 2.5 billion by 2030, at a CAGR of 9.7 percent. The uncommon disease not only impacts the lives of a few people scattered over the world, but the number of people afflicted is directly similar to the world's third most populous country. Genetic testing is a high-level analytic tool that not only aids in diagnosing particular illness manifestations but also in determining the hidden causes of genetic disorders.